Changing the treatment paradigm in myelodysplastic syndromes

Cancer Control

Volumn 15, Issue 4 SUPPL., 2008, Pages 14-28

  Mufti, Ghulam J ^a   Chen, Tara L ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; LENALIDOMIDE; METHYLTRANSFERASE INHIBITOR; THALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CLINICAL TRIAL; CYTOGENETICS; DISEASE COURSE; DRUG TARGETING; GOLD STANDARD; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRON CHELATION; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; REDUCED INTENSITY CONDITIONING; REVIEW; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 55049105415     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480801504s03     Document Type: Review

References (64)

1. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999;340(21):1649-1660.
2. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003;27(2):95-120.
3. Aul C, Giagounidis A, Germing U, et al. Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol. 2002;81(9):485-497.
4. de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 2000;110(3):620-630.
5. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia. 2006;20(10):1661-1672.
6. Barrett AJ, Savani BN. Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol. 2008;45(1):49-59.
7. National Comprehensive Cancer Network Practice Guidelines in Oncology v2.2008. Myelodysplastic syndromes. 09/06/2007 National Comprehensive Cancer Network. http://nccn.org/professionals/physician_gls/PDF/mds.pdf. Accessed May 19, 2008.
8. Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120(2):187-200.
9. Cazzola M, Malcovati L. Myelodysplastic syndromes: coping with ineffective hematopoiesis. N Engl J Med. 2005;352(6):536-538.
10. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96(12):3671-3674.
11. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.
12. Schiffer CA. World Health Organization and International Prognostic Scoring System: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes. Semin Hematol. 2008;45(1):3-7.
13. Ramos F, Fernández-Ferrero S, Suárez D, et al. Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leuk Res. 1999;23(3):283-290.
14. Jansen AJ, Essink-Bot ML, Beckers EA, et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol. 2003;121(2):270-274.
15. Della Porta MG, Malcovati L, Travaglino E, et al. A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes. Blood. 2007;110. Abstract 2453.
16. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.
17. Kao JM, McMillan A, Greenberg PL. International MDS Risk Analysis Workshop (IMRAW)/IPSS re-analyzed: impact of depth of cytopenias on clinical outcomes in MDS. Blood. 2007;110. Abstract 2457.
18. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25(23):3503-3510.
19. Germing U, Gattermann N, Strupp C, et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000;24(12):983-992.
20. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-4395.
21. Schanz J, Estey EH, Steidl C, et al. Multivariate analysis suggests that the prognostic impact of poor cytogenetics is potentially underestimated in the IPSS. Blood. 2007;110. Abstract 248.
22. Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22(3): 538-543.
23. Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008;26(15):2505-2511.
24. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003;102(8):3025-3027.
25. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematologic responses to antithymocyte globulin. Leukemia. 2007;21(7):1436-1441.
26. Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients: a prospective analysis by the GFM. Blood. 2007;110. Abstract 249.
27. Jabbour E, Kantarjian HM, Koller C, et al. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer. 2008;112(5):1089-1095.
28. Besa EC. Myelodysplastic syndromes: recent advances in the biology and therapy of this complex disease. Cancer Therapeutics. 1998;1:52-63.
29. Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol. 2008;45(1):23-30.
30. Silverman LR, Mufti GL. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol. 2005;2(suppl 1): S12-S23.
31. Atallah E, Garcia-Manero G. Treatment strategies in myelodysplastic syndromes. Cancer Invest. 2008;26(2):208-216.
32. Fenaux P, Mufti GJ, Santini V, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 phase III study. Blood. 2007;110. Abstract 817.
33. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20(10): 2429-2440.
34. Mufti GJ, Fenaux P, Hellstrom-Lindberg E, et al. Treatment of high-risk MDS patients (pts) with -7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): effects on overall survival (OS). J Clin Oncol. 2008;26. Abstract 7033.
35. Lim ZY, Ho AYL, Samuel J, et al. Outcomes of MDS patients with chromosome 7 abnormalities treated with 5-azacytidine. Blood. 2007;110. Abstract 1449.
36. Lyons RM, Cosgriff T, Modi S, et al. Results of the initial treatment phase of a study of three alternative dosing schedules of azacitidine (Vidaza®) in patients with myelodysplastic syndromes (MDS). Blood. 2007;110. Abstract 819.
37. Grövdal M, Khan R, Aggerholm A, et al. Maintenance treatment with azacitidine for patients with high risk myelodysplastic syndromes or acute myeloid leukaemia in complete remission after intensive chemotherapy. Blood. 2007;110. Abstract 818.
38. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18(5):956-962.
39. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia. 1997;11(suppl 1):S19-S23.
40. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-1803.
41. Kantarjian HM, O'Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007;109(2):265-273.
42. Kantarjian HM, O'Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007;109(6):1133-1137.
43. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109(1):52-57.
44. Kantarjian H, Garcia-Manero G, O'Brien S, et al. Survival and efficacy of decitabine in myelodysplastic syndromes (MDS), analysis of the 5-day IV dosing regimen. Blood. 2007;110. Abstract 115.
45. Deeg HJ, Guardiola P. Allogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosis. Int J Hematol. 2002;76(suppl 2):29-34.
46. Ho AY, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood. 2004;104(6):1616-1623.
47. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hematopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100(4):1201-1207.
48. Anderson JE. Bone marrow transplantation for myelodysplasia. Blood Rev. 2000;14(2):63-77.
49. Martino R, Caballero MD, Simón JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood. 2002;100(6):2243-2245.
50. Ho AY, Pagliuca A, Kenyon M, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood. 2004;104(6):1616-1623.
51. Laport GG, Sandmaier BM, Storer BE, et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 2008;14(2):246-255.
52. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104(2):579-585.
53. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25(27):4246-4254.
54. Venditti A, Maurillo L, Buccisano F, et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia. 2003;17(11):2178-2182.
55. Scott BL, Storer B, Loken MR, et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant. 2005;11(1):65-73.
56. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96(6):2240-2245.
57. Crane E, List A. Lenalidomide: an immunomodulatory drug. Future Oncol. 2005;1(5):575-583.
58. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol. 2008;87(7):515-526.
59. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549-557.
60. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456- 1465.
61. List A, Wride K, Dewald G, et al. Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion. Leuk Res. 2007;31(suppl 1):S38.
62. Sekeres MA, Maciejewski JP, Giagounidis A, et al. Lenalidomide-induced cytopenias: relationship to hematologic improvement in patients with myelodysplastic syndromes (MDS). Blood. 2007;110. Abstract 821.
63. Pellagatti A, Jädersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007;104(27):11406-11411.
64. Kelaidi C, Eclache V, Fenaux P. The role of lenalidomide in the management of myelodysplasia with del 5q. Br J Haematol. 2008;140(3):267-278.